ArticleBMC infectious diseases2026
Efficacy of Ceftazidime/Avibactam versus colistin methanesulfonate in treating pulmonary infections caused by Gram-negative bacillis after craniocerebral surgery and analysis of risk factors influencing clinical outcomes: a retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to compare the efficacy of Ceftazidime/Avibactam (CAZ/AVI) and Colistin Methanesulfonate (CMS) in the treatment of pulmonary infection caused by Gram-negative bacilli after craniocerebral surgery, and analysis of risk factors influencing clinical outcomes.
methodsWe retrospectively enrolled patients who developed pulmonary infections caused by Gram-negative bacilli following craniocerebral surgery spanning from January 1st, 2023 to June 9th, 2025. These patients were divided into the CAZ/AVI group and the CMS group based on their medication choices. In-hospital mortality and clinical success rate were compared between the two groups. Additionally, logistic regression analysis was performed to assess the association between CAZ/AVI-based treatment regimens and clinical success rate.
resultsThe In-hospital mortality rates of the two groups were 8.51% and 14.63% respectively, both relatively low, and there was no statistical significance (P = 0.367). The clinical success was noted to be significantly higher in CAZ/AVI-based treatment regimens (P = 0.041). In the logistic regression analysis, the clinical success rate was independently associated with the use of CAZ/AVI and the combination of antibiotics. The odds of clinical success rate were 3.062 times higher in patients receiving CAZ/AVI compared to those without CAZ/AVI therapy (95% CI: 1.219-10.646); similarly, the odds ratios (OR) associated with combined antibiotic use was 3.608 (95% CI: 1.235-10.546).
conclusionsCAZ-AVI is more effective than CMS in treating pulmonary infections caused by Gram-negative bacilli after craniocerebral surgery. And when combined with other antibiotics, it can significantly enhance the clinical success rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.